SSTR4 Agonist Derivatives for Controlling Neuronal Hyperactivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease and other CNS disorders lack effective pharmacological tools to inhibit and control neuronal hyperactivity, which contributes to disease progression and cognitive impairment.
Innovation Solution
Development of N-heteroarylalkyl-2-(heterocyclyl and heterocyclylmethyl)acetamide derivatives that act as modulators of the somatostatin receptor 4 (SSTR4), potentially providing a therapeutic approach by controlling neuronal activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Alzheimer's disease are used, then existing therapeutic options are available, but they lack effective pharmacological tools to inhibit and control neuronal hyperactivity
Solution Approach 1:
The patent develops a series of SSTR4 modulator compounds with varying chemical structures (Formula 1 with different R1-R18 substituents) to optimize pharmacological properties. By systematically modifying molecular parameters such as heterocyclic groups, alkyl chains, and functional groups, the invention creates multiple compounds with different potency, selectivity, and pharmacokinetic profiles, thereby providing versatile pharmacological tools while maintaining effective treatment of neuronal hyperactivity
Solution Approach 2:
The patent divides the complex therapeutic challenge into manageable components by developing a library of compounds with distinct structural segments. Each compound in Formula 1 contains specific heterocyclic moieties (e.g., pyrrolidinyl, piperidinyl, morpholinyl) and substituent patterns that can be independently optimized. This segmentation allows systematic exploration of structure-activity relationships to address different aspects of Alzheimer's pathology
2Reliability
If SSTR4 agonists are developed to control neuronal activity, then neuronal hyperactivity can be inhibited, but the complexity of the compound structure increases
Solution Approach 1:
The patent optimizes the balance between structural complexity and biological activity by systematically varying substituents in Formula 1. Specific heterocyclic groups (R10: azetidin-1-ylmethyl, pyrrolidin-1-ylmethyl, piperidin-1-ylmethyl, morpholin-1-ylmethyl) and substituent patterns (R1-R9) are tuned to achieve high SSTR4 selectivity and potency while maintaining reasonable molecular weight and lipophilicity for CNS penetration
Solution Approach 2:
The patent uses the SSTR4 receptor as an intermediary target to indirectly control neuronal hyperactivity. Rather than directly targeting ion channels or neurotransmitter release sites, the compounds modulate G-protein coupled SSTR4 receptors, which then exert downstream effects on neuronal excitability through cAMP pathway regulation, providing a more selective and controllable mechanism
Data Source
AI summary
Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein L, n, R1, R2, R6, R7, R8, R9, R10, X3, X4 and X5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.